SCHEMBL474462

SCHEMBL474462

CN1C(=O)COc2c(C(=O)Cc3ccc(Br)cc3Cl)cccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.36
USP2 O75604 1/20 0.36
SLC6A4 P31645 5/20 0.36
KCNH2 Q12809 5/20 0.36
HTR2A P28223 1/20 0.36
HRH1 P35367 1/20 0.36
HTR3A P46098 1/20 0.36
PDE4D Q08499 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
MALT1 Q9UDY8 1/20 0.34
HTR1A P08908 4/20 0.34
HTR1D P28221 4/20 0.34
HTR1B P28222 4/20 0.34
TSHR P16473 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474373 0.80 MAPT (0.35) CASP2USP2TDP1LMNAMAPT
SCHEMBL474711 0.80 MAP3K5 (0.39) CASP2USP2
SCHEMBL474440 0.80 CASP2 (0.35) CASP2SLC6A4KCNH2HTR2AHRH1
SCHEMBL474583 0.79 SLC6A4 (0.35) CASP2USP2SLC6A4KCNH2HTR2A
SCHEMBL474625 0.78 PTGER3 (0.42) CASP2USP2LMNAMAPTTSHR
SCHEMBL2816062 0.76 CASP2 (0.35) CASP2USP2MAPTMALT1TSHR
SCHEMBL7288891 0.73 SLC6A4 (0.40) USP2SLC6A4KCNH2HTR2AHRH1
SCHEMBL31133320 0.72 SLC6A4 (0.41) SLC6A4KCNH2HTR2AHRH1HTR3A
SCHEMBL1339079 0.72 SLC6A4 (0.41) SLC6A4KCNH2HTR2AHRH1HTR3A
Hydrochloric Acid SCHEMBL7288897 0.71 SLC6A4 (0.40) SLC6A4KCNH2HTR2AHRH1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411365-B1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-03-19 EP disclosed
US-20130172335-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2013-07-04 US disclosed
US-8450313-B2 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds HOFFMANN-LA ROCHE INC. (US) 2013-05-28 US disclosed
US-8268820-B2 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-09-18 US disclosed
US-20120232071-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HUNZIKER DANIEL (CH) 2012-09-13 US disclosed
EP-2411365-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
WO-2010108903-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172335-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R CASP2 4574/4885USP2 4222/4885SLC6A4 549/4885
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R CASP2 4608/4885USP2 4305/4885SLC6A4 564/4885
US-20120232071-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R CASP2 4574/4885USP2 4222/4885SLC6A4 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.